• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

急性髓系白血病细胞对柔红霉素和阿糖胞苷的耐药机制：文献综述

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review.

作者信息

Arwanih Elly Y, Louisa Melva, Rinaldi Ikhwan, Wanandi Septelia I

机构信息

Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, IDN.

Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, IDN.

出版信息

Cureus. 2022 Dec 31;14(12):e33165. doi: 10.7759/cureus.33165. eCollection 2022 Dec.

DOI:10.7759/cureus.33165
PMID:36726936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9885730/
Abstract

Acute myeloid leukemia (AML) is a hematological malignancy commonly found in adult patients. Low overall survival and resistance to therapy are the main issues in AML. The first line of treatment for AML chemotherapy is the induction phase, namely, the phase to induce remission by administering a combination of daunorubicin (DNR) for three days followed by administration of cytarabine (Ara-C) with continuous infusion for seven days, which is referred to as "3 + 7." Such induction therapy has been the standard therapy for AML for the last four decades. This review article is made to discuss daunorubicin and cytarabine from their chemical structure, pharmacodynamics, pharmacokinetics, and mechanisms of resistance in AML.

摘要

急性髓系白血病（AML）是一种常见于成年患者的血液系统恶性肿瘤。总生存率低和对治疗的耐药性是AML的主要问题。AML化疗的一线治疗是诱导期，即通过连续三天给予柔红霉素（DNR），然后连续七天持续输注阿糖胞苷（Ara-C）来诱导缓解的阶段，这被称为“3 + 7”。在过去的四十年里，这种诱导治疗一直是AML的标准治疗方法。这篇综述文章旨在从柔红霉素和阿糖胞苷的化学结构、药效学、药代动力学以及AML的耐药机制方面进行讨论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/59e56f176fe1/cureus-0014-00000033165-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/bdf4e01ac67d/cureus-0014-00000033165-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/e0e641b0f456/cureus-0014-00000033165-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/59e56f176fe1/cureus-0014-00000033165-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/bdf4e01ac67d/cureus-0014-00000033165-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/e0e641b0f456/cureus-0014-00000033165-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b000/9885730/59e56f176fe1/cureus-0014-00000033165-i03.jpg

相似文献

1
Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review.急性髓系白血病细胞对柔红霉素和阿糖胞苷的耐药机制：文献综述
Cureus. 2022 Dec 31;14(12):e33165. doi: 10.7759/cureus.33165. eCollection 2022 Dec.
2
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.米托蒽醌与柔红霉素用于诱导巩固化疗——小剂量阿糖胞苷对维持缓解的价值以及老年急性髓系白血病预后因素评估：最终报告。欧洲癌症研究与治疗组织及荷兰 - 比利时血液肿瘤协作组霍冯小组
J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872.
3
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.阿糖胞苷和柔红霉素用于治疗急性髓性白血病。
Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780. doi: 10.1080/14656566.2017.1391216. Epub 2017 Oct 20.
4
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.柔红霉素和阿糖胞苷治疗某些预后不良的急性髓系白血病：系统文献回顾。
Expert Rev Clin Pharmacol. 2019 Mar;12(3):197-218. doi: 10.1080/17512433.2019.1573668. Epub 2019 Feb 6.
5
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.阿柔比星联合阿糖胞苷与柔红霉素联合阿糖胞苷治疗初治急性髓系白血病患者的疗效比较：一项丹麦全国性III期试验。丹麦血液学会急性髓系白血病研究组，丹麦
Leukemia. 1991 Jun;5(6):510-6.
6
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.在一项丹麦全国性III期试验中，接受阿柔比星或柔红霉素加阿糖胞苷治疗后进行强化巩固化疗的急性髓性白血病患者继发性恶性肿瘤的长期生存与发展。丹麦血液学学会AML研究组
Leukemia. 1997 Jan;11(1):37-41. doi: 10.1038/sj.leu.2400514.
7
[The Mechanism of Artesunate Combined with Cytarabine and/or Daunorubicin on the Apoptosis of MV4-11 MLL-rearranged Acute Myeloid Leukemia Cell Line].青蒿琥酯联合阿糖胞苷和/或柔红霉素对MV4-11 MLL重排急性髓系白血病细胞系凋亡的作用机制
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Dec;30(6):1724-1729. doi: 10.19746/j.cnki.issn.1009-2137.2022.06.015.
8
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.柔红霉素、阿糖胞苷和氟达拉滨（DAF）用于复发或难治性急性髓系白血病的缓解诱导。安全性、耐受性及早期结果评估——波兰成人白血病组（PALG）的初步研究
Ann Hematol. 2008 May;87(5):361-7. doi: 10.1007/s00277-007-0421-4. Epub 2007 Dec 12.
9
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.一项关于伏司泊达（PSC 833）联合柔红霉素和阿糖胞苷逆转初治老年急性髓系白血病患者多药耐药性的剂量探索性研究。
Hematol J. 2000;1(6):411-21. doi: 10.1038/sj.thj.6200050.
10
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.阿糖胞苷持续输注与每日短程输注联合克拉屈滨治疗儿童急性髓系白血病的中期比较
J Clin Oncol. 2002 Oct 15;20(20):4217-24. doi: 10.1200/JCO.2002.10.006.

引用本文的文献

1
The antitumor effects and apoptotic mechanism of 20(S)-Protopanaxadiol in acute myeloid leukemia.20(S)-原人参二醇对急性髓系白血病的抗肿瘤作用及凋亡机制
J Ginseng Res. 2025 May;49(3):306-314. doi: 10.1016/j.jgr.2025.03.006. Epub 2025 Mar 20.
2
Dual targeting of CXC chemokine receptor 4 and multidrug resistance protein 1 by ZIN056 effectively combat daunorubicin resistance in acute myeloid leukemia cells.ZIN056对CXC趋化因子受体4和多药耐药蛋白1的双重靶向作用可有效对抗急性髓系白血病细胞中的柔红霉素耐药性。
Med Oncol. 2025 Mar 13;42(4):106. doi: 10.1007/s12032-025-02656-x.
3
Transforming growth factor-β1 and vascular endothelial growth factor levels in senile acute myeloid leukemia and correlation with prognosis.

本文引用的文献

1
DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.DNMT3A R882H 突变通过调节 NRF2/NQO1 通路驱动急性髓系白血病对柔红霉素耐药。
Cell Commun Signal. 2022 Oct 27;20(1):168. doi: 10.1186/s12964-022-00978-1.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
A review of FLT3 inhibitors in acute myeloid leukemia.
老年急性髓系白血病中转化生长因子-β1和血管内皮生长因子水平及其与预后的相关性
World J Clin Cases. 2024 Jul 16;12(20):4121-4129. doi: 10.12998/wjcc.v12.i20.4121.
4
Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation.药理学p38丝裂原活化蛋白激酶抑制剂SB203580通过促进晚期凋亡、S期细胞生长停滞和miR-328-3p上调，增强急性髓系白血病干细胞系KG1a对柔红霉素的化疗敏感性。
Saudi Pharm J. 2024 Jun;32(6):102055. doi: 10.1016/j.jsps.2024.102055. Epub 2024 Mar 30.
5
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.对新诊断的急性髓系白血病患者进行分层，根据白血病原始细胞 P-糖蛋白表型，给予化疗联合齐多夫定持续 72 小时输注。
Cancer Chemother Pharmacol. 2024 Jun;93(6):595-604. doi: 10.1007/s00280-024-04656-6. Epub 2024 Feb 26.
6
Unveiling the mechanisms and challenges of cancer drug resistance.揭示癌症药物耐药性的机制和挑战。
Cell Commun Signal. 2024 Feb 12;22(1):109. doi: 10.1186/s12964-023-01302-1.
7
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.氯喹通过抑制自噬通路增强化疗药物对急性髓系白血病的疗效。
Acta Pharmacol Sin. 2023 Nov;44(11):2296-2306. doi: 10.1038/s41401-023-01112-8. Epub 2023 Jun 14.
FLT3 抑制剂在急性髓系白血病中的研究进展。
Blood Rev. 2022 Mar;52:100905. doi: 10.1016/j.blre.2021.100905. Epub 2021 Nov 3.
4
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.白血病和淋巴瘤中阿糖胞苷治疗的反应与毒性：从剂量难题到药物基因组生物标志物
Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966.
5
FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients.FLT3内部串联重复突变和FLT3配体血浆水平与印度尼西亚急性髓系白血病患者的一年生存率无关。
Onco Targets Ther. 2021 Feb 26;14:1479-1486. doi: 10.2147/OTT.S282842. eCollection 2021.
6
Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.急性髓系白血病中的突变：关键概念与新出现的争议
Front Oncol. 2020 Dec 23;10:612880. doi: 10.3389/fonc.2020.612880. eCollection 2020.
7
Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance.p53、自噬与化疗耐药性之间的三角关系。
Int J Mol Sci. 2020 Nov 26;21(23):8991. doi: 10.3390/ijms21238991.
8
Relapsed or primary refractory AML: moving past MEC and FLAG-ida.复发或原发性难治性 AML：超越 MEC 和 FLAG-ida。
Curr Opin Hematol. 2020 Mar;27(2):108-114. doi: 10.1097/MOH.0000000000000561.
9
Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.DNMT3A R882 突变等位基因比例对中国 AML 患者预后的影响。
J Transl Med. 2019 Jul 10;17(1):220. doi: 10.1186/s12967-019-1959-3.
10
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.急性髓细胞白血病，第 3.2019 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.